Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | HLCS | P50747 | 6/20 | 0.64 |
| ▸ | CA12 | O43570 | 6/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899174 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4757050 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13274150 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5903676 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13524253 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10171679 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12238074 | 1.00 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL24653263 | 0.99 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15130533 | 0.96 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL26902859 | 0.93 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173079-A2 | NONCOVALENTLY BRANCHED OLIGONUCLEOTIDE COMPOSITIONS | ATALANTA THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | REVVITY HEALTH SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11549017-B2 | NIR to SWIR fluorescent compounds for imaging and detection | PERKINELMER HEALTH SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-10995004-B2 | Method for functionalizing carbon nanoparticles and compositions | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200207627-A1 | METHOD FOR FUNCTIONALIZING CARBON NANOPARTICLES AND COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-02 | — | — | US | disclosed |
| WO-2020132588-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | KLEO PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-3228631-B1 | TREATING RESPIRATORY CONDITIONS | TLA TARGETED IMMUNOTHERAPIES AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| EP-2717940-B1 | TREATING CONDITIONS ASSOCIATED WITH METABOLIC SYNDROME | TLA TARGETED IMMUNOTHERAPIES AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-10451620-B2 | Treating conditions associated with metabolic syndrome | TLA TARGETED IMMUNOTHERAPIES AB (SE) | 2019-10-22 | — | — | US | disclosed |
| US-10429385-B2 | Treating conditions associated with sepsis | TLA TARGETED IMMUNOTHERAPIES AB (SE) | 2019-10-01 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090048123-A1 | Reagentless and Reusable Biosensors with Tunable Differential Binding Affinities and Methods of Making | THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-02-19 | — | — | US | disclosed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008134731-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080262254-A1 | Sphingolipids | ETTMAYER PETER | 2008-10-23 | — | — | US | disclosed |
| US-20080262254-A1 | Sphingolipids | ETTMAYER PETER | 2008-10-23 | — | — | US | disclosed |
| US-7435386-B2 | Biorecognition element, a modular arm element labeled with a second signaling module, a detector for detecting a change in fluorescence resonance energy transfer (FRET) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008106657-A2 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | TDP1 2067/4885MEN1 227/4885ABL1 4641/4885 |
| US-20200207627-A1 | METHOD FOR FUNCTIONALIZING CARBON NANOPARTICLES AND COMPOSITIONS | TERT, CA13, PCCA | TDP1 3965/4885MEN1 1660/4885ABL1 1064/4885 |
| US-10995004-B2 | Method for functionalizing carbon nanoparticles and compositions | TERT, CA13, PCCA | TDP1 3965/4885MEN1 1660/4885ABL1 1064/4885 |
| US-20080262254-A1 | Sphingolipids | SGMS2, SGMS1, SGPL1 | TDP1 1903/4885MEN1 376/4885ABL1 2776/4885 |
| US-11549017-B2 | NIR to SWIR fluorescent compounds for imaging and detection | SMARCD1, SMARCE1, SMARCB1 | TDP1 1295/4885MEN1 1886/4885ABL1 4400/4885 |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | SMARCD1, SMARCE1, SMARCB1 | TDP1 1295/4885MEN1 1886/4885ABL1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.